Shots:

• Boehringer to receive payments to cover start-up expenses and pre-approval initiatives for a successful commercial launch. Additionally- it receives mid-twenties percentage of net sales in the 1^st yr. of commercialization- which decreases to a low double-digit/high single-digit percentage in the 2^nd and 3^rd year respectively
• G1 will book revenue in the selective territories and retain global development and commercialization rights to Trilaciclib. In the US and Puerto Rico- G1 will lead marketing- market access- and medical engagement initiatives while Boehringer will control salesforce engagements
• G1 will not make any payments after the expiration of 3yrs. agreement and does not extend the agreement to additional indications for the therapy. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with CT and has received the FDA’s BT designation and has submitted NDA for SCLC in Jun’2020

Click here to read full press release/ article | Ref: Buisnesswire | Image: Boehringer Ingelheim